Novavax (NVAX) Announces $388M Funding from CEPI for COVID-19 Vaccine

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. LEVI
2. APLD
3. LULU
4. DVN
5. WOLF
6. ANGO
7. COST
8. BCO
9. NATL
10. STZ

Go back to Novavax (NVAX) Announces $388M Funding from CEPI for COVID-19 Vaccine

Novavax to Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing

May 11, 2020 4:02 PM EDT

Funds clinical development of NVX-CoV2373 through Phase 2Supports rapid scale-up of vaccine manufacturingAllows for increased production of Matrix-M adjuvantReserves global large-scale manufacturing capacity

GAITHERSBURG, Md., May 11, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of NVX-CoV2373, Novavax coronavirus vaccine... More